Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Ruben A. Mesa(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Donal P. McLornan(University College Hospital), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Aaron T. Gerds(Cleveland Clinic), Marek Hus(Medical University of Lublin), Alessandro M. Vannucchi(University of Florence), Claire Harrison(University of Namur), Vikas Gupta(Princess Margaret Cancer Centre), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barbara Klencke, Timothy Devos(Rega Institute for Medical Research), Mei Huang(Tongji Hospital), Bryan Strouse(Sierra Engineering (United States)), Stephen T. Oh(Washington University in St. Louis), John Catalano(Frankston Hospital), Jean‐Jacques Kiladjian(Assistance Publique – Hôpitaux de Paris)
Cited by 63
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k